'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Biocon has increased 14.83% to Rs 3941.9 crore. Sales of Generics segment has gone up 5.64% to Rs 696.50 crore (accounting for 17.29% of total sales). Sales of Biosimilars segment has gone up 17.97% to Rs 2,457.80 crore (accounting for 61.01% of total sales). Sales of Research service segment has gone up 10.74% to Rs 874.50 crore (accounting for 21.71% of total sales). Inter-segment sales came down from Rs 99.50 crore to Rs 86.90 crore.
Profit before interest, tax and other unallocable items (PBIT) has slumped 88.68% to Rs 130.30 crore. PBIT of Generics reported loss of Rs 67.00 crore compared to profit of Rs 16.90 crore. PBIT of Biosimilars segment fell 90.98% to Rs 96.00 crore (accounting for 73.68% of total PBIT). PBIT of Research ...
Pleaselogin & subscribe to view the full report.
More Reports
-
(13-Jan-2026)
HCL Technologies
Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
-
(13-Jan-2026)
Tata Consultancy Services
Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
-
(12-Jan-2026)
Krishana Phoschem
Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
-
(11-Jan-2026)
Avenue Supermarts
Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026
|
|